In BRAFV600-mutant NSCLC, resistance can occur after treatment with either BRAF inhibitors as single agents or upon dual BRAF and MEK inhibition by activating mutations in KRAS or NRAS [74,106,107]. Here, NRAS is linked to non-small cell lung carcinoma.